People who carry the APOE e4 form of the APOE gene appear to have a higher risk of serious brain-swelling and brain-bleeding complications from lecanemab or donanemab, and the FDA recommends testing for this gene before treatment.
Notes on verification
Confirmed by FDA press release, official drug label, and independent medical genetics literature; consistent across multiple high-quality sources. [tier=bronze indep_score=0.539 clusters=2 claim_tier=notable]
Sources
- Dementia - Diagnosis and treatment (seed:health_and_medicine)
- https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval (corroboration)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf (corroboration)
- https://www.ncbi.nlm.nih.gov/books/NBK605938/ (corroboration)
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180672/ (corroboration)